{
  "trial_id": "NCT01044628",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "smoking and obstructive disease with FEV1/FVC < 70%",
      "label": "met"
    },
    {
      "criterion": "presence of mild-to-moderate daytime hypoxemia with a daytime PaO2 in the range of 56-69 mmHg",
      "label": "met"
    },
    {
      "criterion": "patients fulfilling our definition of nocturnal oxygen desaturation: >= 30% of the recording time with transcutaneous arterial oxygen saturation < 90%",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with severe hypoxemia fulfilling the usual criteria for continuous oxygen therapy at study entry",
      "label": "triggers"
    },
    {
      "criterion": "Patients with proven sleep apnea (defined by an apnea/hypopnea index of >=15 events/hour) or suspected sleep apnea on oximetry tracings",
      "label": "triggers"
    }
  ],
  "notes": "Patient has multifactorial chronic hypoxemia and dyspnea thought due to diastolic CHF, pulmonary hypertension thought secondary to a chronic ASD and COPD on 5L home oxygen. Patient tolerated an inpatient sildenafil trial without hypotension.",
  "_meta": {
    "topic_id": "16",
    "trial_id": "NCT01044628",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}